Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Portfolio Pulse from
Ginkgo Bioworks has been awarded a $9.4 million subcontract in partnership with Carnegie Mellon University to develop implantable cell-based bioelectronic devices for treating endocrine disorders. This project is part of ARPA-H's REACT program.
December 17, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ginkgo Bioworks has secured a $9.4 million subcontract to develop bioelectronic devices for endocrine disorders, enhancing its position in cell programming and biosecurity.
The $9.4 million subcontract signifies a significant investment in Ginkgo Bioworks' capabilities in cell engineering, potentially leading to advancements in treating endocrine disorders. This partnership with Carnegie Mellon and involvement in ARPA-H's REACT program could enhance Ginkgo's reputation and market position, likely having a positive short-term impact on its stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90